Core Viewpoint - Can-Fite BioPharma Ltd. has announced a 1-for-3,000 reverse split of its ordinary shares, which will take effect on January 2, 2026, with the first trading of the consolidated shares on January 5, 2026 [1][4]. Share Structure Changes - Each outstanding 3,000 pre-split ordinary shares will combine into one new ordinary share automatically, with no action required from shareholders [2]. - The ratio of ordinary shares underlying the Company's American Depositary Shares (ADSs) will change from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, effective January 5, 2026 [2][3]. - The total number of outstanding ordinary shares will decrease from 42 billion to 14 million as a result of the reverse split [4]. Impact on ADS Holders - For ADS holders, the ratio change equates to a one-for-twenty ADS split, requiring the exchange of every 20 ADSs for one new ADS [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [6]. Ownership and Voting Power - The reverse split and ADS ratio change will not affect shareholders' percentage ownership or voting power, aside from minimal effects from fractional shares [5]. Market Expectations - The ADS price is expected to increase proportionally due to the change in the ADS ratio, although there is no assurance that the price will be equal to or greater than twenty times the pre-split price [7]. Company Overview - Can-Fite BioPharma Ltd. is focused on developing small-molecule drugs for oncological and inflammatory diseases, with its lead drug candidate, Piclidenoson, in Phase III trials for psoriasis [8]. - The company is also advancing Namodenoson, which is in various stages of trials for liver cancer and has received Orphan Drug Designation in the U.S. and Europe [8].

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.NYSE : NVONovo NordiskToday's Change( 7.42 %) $ 3.57Current Price$ 51.67Key Data PointsMarket Cap$162BDay's Range$ 51.05 - $ 53.2052wk Range$ 43.08 - $ 93.80Volume2.1MAvg Vol16MGross Margin81.93 %Dividend Yield3.59 %Novo Nordisk (NVO +7.42%), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-d ...

Core Viewpoint - Theralase Technologies Inc. has successfully closed a non-brokered private placement offering, raising approximately $CAN 1,334,650 to support its clinical study and general corporate purposes [1][2][3]. Group 1: Offering Details - The company issued a total of 7,850,882 Units at a price of $CAN 0.17 per Unit, resulting in gross proceeds of about $CAN 1,334,650 [2]. - Each Unit consists of one common share and one common share purchase warrant, with the warrant allowing the holder to acquire an additional common share at an exercise price of $CAN 0.21 for five years [2]. - A finder's fee of $31,658 was paid, which included $15,470 in cash and $16,188 in common shares, along with the issuance of 186,221 non-transferable finder warrants [4]. Group 2: Use of Proceeds - The proceeds from the financing will be utilized to advance the Phase II Non-Muscle Invasive Bladder Cancer clinical study, as well as for working capital and general corporate purposes [3]. Group 3: Regulatory and Compliance Information - All securities issued under the Offering will be subject to a four-month and one-day hold period, expiring on April 24, 2026, and the Offering is pending final acceptance from the TSX Venture Exchange [6].

A big data point this morning that is a great sign for Trumpomics. Welcome to the Big Money Show. I'm Taylor Riggs along with my co-hosts Lydia who Lou Basses Jackie D'Angelus and with us for the entire hour Forbes media chairman and editor-inchief Steve Forbes.Great to have you. >> Good to be here. Thank you.So the numbers out this morning, GDP blowing past estimates. The US economy growing at 4.3% in the third quarter. That is the strongest pace in 2 years.That is major momentum heading into Q4. And it's ...

MEXICO CITY, Dec. 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that today it completed the payment of the cash dividend previously announced through a Notice of Rights filed with the Mexican Stock Exchange (Bolsa Mexicana de Valores). The dividend amounted to $0.200000 Mexican pesos per share on its common stock ...

US stocks tipped higher on Tuesday, with the S&P 500 clinching a fresh record, as Wall Street shrugged off fresh data that showed surprisingly strong growth in the US economy over the summer that led investors to trim bets on near-term interest-rate cuts. The S&P 500 (^GSPC) edged up 0.5% to notch a record close of 6,909.79. The tech-heavy Nasdaq Composite (^IXIC) rose 0.6%. The blue-chip benchmark Dow Jones Industrial Average (^DJI) gained around 0.2%. The major averages extended gains for a fourth strai ...

Wage Garnishments for Defaulted Student Loans - The Department of Education will begin garnishing wages for defaulted federal student loan borrowers starting January 7, with approximately 1,000 borrowers notified initially [2] - Borrowers who default, typically after not making payments for over 270 days, may have up to 15% of their income garnished to cover missed payments [3] - As of September 30, 2025, there are 5.2 million borrowers in default, with nearly 6.6 million more delinquent between one month and one year [4] Economic Growth and Federal Reserve - The U.S. economy grew at an annual rate of 4.3% in the third quarter, surpassing the expected 3.2% growth, driven by a decrease in imports and a 3.5% rise in consumer spending [25][26] - The Federal Reserve is scheduled to meet on January 27 and 28, with expectations to hold interest rates steady after recent cuts aimed at preventing job market slowdown [27][28] - Fed officials face a dilemma between lowering rates to support employment and maintaining higher rates to combat inflation, as both metrics have shown concerning trends [29][30] Novo Nordisk and FDA Approval - Novo Nordisk's stock surged approximately 8% following FDA approval of its Wegovy pill for weight management, expected to launch in early January [31][32] - The approval positions Novo Nordisk favorably against competitors like Eli Lilly, whose weight-loss pill is anticipated for approval in the first quarter of 2026 [33]

Core Viewpoint - Truist Securities has raised its price target on Cytokinetics, Inc. to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following the regulatory approval of MYQORZO [1] Group 1: Regulatory Approval and Market Potential - The recent approval of MYQORZO, which features a differentiated label, positions it to become a significant revenue driver in obstructive hypertrophic cardiomyopathy (oHCM) [2] - Truist updated its model to estimate worldwide peak sales for MYQORZO in oHCM at $3.7 billion, slightly below the $3.8 billion consensus estimate [2] Group 2: Revenue Projections and Launch Expectations - A steady launch of MYQORZO is expected to begin in early 2026, with performance anticipated to be at least comparable to the launch trajectory of Camzyos [3] - Truist modeled fiscal 2026 aficamten revenue at $106 million, aligning with consensus expectations [3] - Looking ahead, the analyst projects worldwide peak adjusted total revenue of $4.6 billion in 2035, marginally above the $4.5 billion consensus estimate [3]

Core Viewpoint - Jones Trading initiated coverage on MindMed (NASDAQ: MNMD) with a Buy rating and a $61 price target, highlighting the company's position in the expanding field of psychedelic-based neuropsychiatric treatments [1] Group 1: Company Positioning - MindMed is well positioned to benefit from favorable trends in the development of psychedelic agents for mental health [2] - Strong clinical data from earlier-stage trials is expected to lead to positive Phase III outcomes for MindMed's lead asset, MM120, in treating generalized anxiety disorder and major depressive disorder [2] Group 2: Clinical and Regulatory Considerations - There are unique clinical and regulatory risks associated with MM120 due to its relationship with LSD, which is classified as a Schedule I substance in the United States [3] - Compelling Phase III data could support eventual regulatory approval, and LSD's long history may enhance awareness and facilitate rapid commercial uptake if approved [3] Group 3: Market Performance and Opportunities - Despite a strong stock performance in 2025, with shares up approximately 69% year to date, the market is perceived to underestimate the long-term opportunity while overestimating clinical and regulatory hurdles [4]

Key Takeaways BMY will give Eliquis free to Medicaid and donate more than 7 tons of its active ingredient. Eliquis is Bristol Myers Squibb's top drug, posting $11B in sales in the first nine months of 2025. The government deal grants BMY three years of tariff relief and no future pricing mandates.Bristol Myers Squibb (BMY) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active phar ...